Table D25. Morbidity outcomes 4

| Author, Year  Trial Name | Morbidity Outcome 4 | Description of Timing of Measurement of Outcome | Data source | N | Results |
| --- | --- | --- | --- | --- | --- |
| Janson et al., 200320 NA | Eosinophils cationic protein at week 7; between group difference in change from baseline to final visit at week 7 (95% CI) | collected at week 1, week 2, and week 7 | sputum sample | G1: 29 G2: 29 | G1: 231 (203) G2: 324 (346)  Between group difference: -72 (-8 to 63), p= 0.29 |
| Janson et al., 200921  NA | Tryptase > 1 microgram/L  Percentage of neutrophil counts | collected once at the end of each time period; During intervention(T0-T1), following intervention (T1-T2), and for entire study duration (T0-T2) | sputum sample | NA | Tryptase>1 microgram/L; Odds ratio  T0-T1:  G1: 0.1  G2: 0.2  p: 0.29  T1-T2:  G1: 0.1  G2: 0.4  p: 0.24  T0-T2:  G1: 0.0  G2: 0.1  p: 0.08  Mean change in neutrophil %  T0-T1:  G1: 2.7  G2:: -1.7  p: 0.41  T1-T2:  G1: 2.6  G2. -5.2  p: 0.18  T0-T2:  G1: 5.3  G2: -6.7  p: 0.04 |
| Katon et al., 200128 NA  Ludman et al., 200329 NA  Van Korff et al., 200330 NA | Functional impairment   (Von Korff et al.) | BL, 3, 6, 9, 12 months | Self-report , SF-36 Role-Emotional Scale( using imputed data and adjusting for age, sex, chronic disease score, neuroticism, and baseline SCL) | **BL** G1: 194 G2: 192  **3 mos** G1: 186 G2: 186  **6 mos** G1: 181 G2: 170  **9 mos** G1: 175 G2: 164  **12 mos** G1: 174 G2: 153 | **3 mos** mean (SD) G1: 67.2 (35.6) G2: 68.3 (35.6) 95% CI, NR  p: NR  **6mos** mean (SD) G1: 67.8 (36.5) G2: 72.1 (31.8) 95% CI, NR  p: NR  **9mos** mean (SD) G1: 70.8 (36.3) G2: 71.0 (34.3) 95% CI, NR  p: NR  **12mos** mean (SD) G1: 75.9 (32.2) G2: 73.9 (36.2) 95% CI, NR  p: NR  Effects: Intervention Estimate: -1.52 (2.21) T-statistic: 0.69 p: 0.49  Time Estimate: 2.51 (0.88) T-statistic: 2.86 p: 0.004  Intervention x time Estimate: 0.32 (1.16) T-statistic: 0.28 p: 0.78 |
| Pearce et al., 200839  Cardiovascular Risk Education and Social Support (CaRESS) Trial | SF-36 Physical composite score | 3 times over a 12-month period, at baseline, visit 5, and endpoint | SF-36 Health Survey | **BL** G1 + G2: 107 G3: 88  **Midpoint** G1 + G2: 84 G3: 74  **EP** G1 + G2: 74 G3: 72 | **BL** G1 + G2: 38.0 G3: 40.9 95% CI, NR p: 0.0829 (unadjusted), NA (adjusted)  **Midpoint** G1 + G2: 42.7 G3: 42.6 95% CI, NR p: 0.4145 (unadjusted), 0.9598 (adjusted)  **EP** G1 + G2: 41.4 G3: 41.6 95% CI, NR p: 0.4345 (unadjusted), 0.9056 (adjusted) |
| Schneider et al., 200849  NA | Occurrence of MI | 6 and 12 months for the past 6 months | Medical chart review | G1: 47  G2: 38 | G1: NR  G2: NR  95% CI, NR  p: NR  Numbers not reported, but results were not significant |